DK1339406T3 - Piperazinderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af lidelser i centralnervesystemet - Google Patents

Piperazinderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af lidelser i centralnervesystemet

Info

Publication number
DK1339406T3
DK1339406T3 DK01986458T DK01986458T DK1339406T3 DK 1339406 T3 DK1339406 T3 DK 1339406T3 DK 01986458 T DK01986458 T DK 01986458T DK 01986458 T DK01986458 T DK 01986458T DK 1339406 T3 DK1339406 T3 DK 1339406T3
Authority
DK
Denmark
Prior art keywords
processes
preparation
treatment
nervous system
central nervous
Prior art date
Application number
DK01986458T
Other languages
Danish (da)
English (en)
Inventor
Wayne Everett Childers
Michael Gerard Kelly
Sharon Joy Rosenzweig-Lipson
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK1339406T3 publication Critical patent/DK1339406T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
DK01986458T 2000-11-28 2001-11-27 Piperazinderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af lidelser i centralnervesystemet DK1339406T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25330100P 2000-11-28 2000-11-28
US29781401P 2001-06-13 2001-06-13

Publications (1)

Publication Number Publication Date
DK1339406T3 true DK1339406T3 (da) 2004-09-27

Family

ID=26943115

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01986458T DK1339406T3 (da) 2000-11-28 2001-11-27 Piperazinderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af lidelser i centralnervesystemet

Country Status (25)

Country Link
US (3) US6469007B2 (ru)
EP (1) EP1339406B1 (ru)
JP (1) JP4198989B2 (ru)
KR (1) KR100835552B1 (ru)
CN (1) CN100352437C (ru)
AR (1) AR035603A1 (ru)
AT (1) ATE269078T1 (ru)
AU (2) AU3765402A (ru)
BR (1) BR0115609A (ru)
CA (1) CA2428039C (ru)
DE (1) DE60103927T2 (ru)
DK (1) DK1339406T3 (ru)
EA (1) EA005925B1 (ru)
ES (1) ES2222401T3 (ru)
HK (1) HK1057864A1 (ru)
HU (1) HUP0400551A2 (ru)
IL (1) IL156098A0 (ru)
MX (1) MXPA03004677A (ru)
NO (1) NO325501B1 (ru)
NZ (1) NZ526150A (ru)
PL (1) PL363219A1 (ru)
PT (1) PT1339406E (ru)
TR (1) TR200401546T4 (ru)
TW (1) TWI224102B (ru)
WO (1) WO2002044142A2 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432826B1 (en) * 1999-11-29 2002-08-13 Applied Materials, Inc. Planarized Cu cleaning for reduced defects
US20060287335A1 (en) * 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
US20060223824A1 (en) * 2000-11-28 2006-10-05 Wyeth Serotonergic agents
EP1408976B3 (en) 2001-07-20 2010-08-25 Psychogenics Inc. Treatment for attention-deficit hyperactivity disorder
US7091349B2 (en) 2002-03-12 2006-08-15 Wyeth Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution
EP1483256A2 (en) 2002-03-12 2004-12-08 Wyeth Process for making chiral 1,4-disubstituted piperazines
US7361773B2 (en) 2002-03-12 2008-04-22 Wyeth Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
NZ535168A (en) 2002-03-12 2006-03-31 Wyeth Corp Process for synthesizing chiral N-aryl piperazines
GB0219961D0 (en) * 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US20040192730A1 (en) * 2003-03-13 2004-09-30 Dynogen Pharmaceuticals, Inc. Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction
PA8626301A1 (es) * 2004-03-19 2006-12-07 Wyeth Wyeth Proceso para preparar derivados de n-aril-piperazina
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
US20070099931A1 (en) * 2004-03-19 2007-05-03 Wyeth Pharmaceutical dosage forms and compositions
KR100646337B1 (ko) * 2004-06-30 2006-11-23 주식회사 롯데기공 보일러의 누수 감지방법
WO2006044596A2 (en) * 2004-10-15 2006-04-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multi-domain amphipathic helical peptides and methods of their use
KR20070112797A (ko) * 2005-03-01 2007-11-27 와이어쓰 결정질 및 비결정질4-시아노-ｎ-((2ｒ)-2-[4-(2,3-디히드로-벤조[1,4]디옥신-5-일)-피페라진-1-일]-프로필)-ｎ-피리딘-2-일-벤즈아미드염산염
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
BRPI0611948A2 (pt) * 2005-06-17 2010-10-13 Wyeth Corp compostos úteis como inibidores de serotonina e agonistas de antagonista de 5-ht1a
WO2007089616A2 (en) 2006-01-26 2007-08-09 The University Of Rochester Inhibiting amyloid-beta peptide/rage interaction at the blood-brain barrier
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200831096A (en) * 2006-11-28 2008-08-01 Wyeth Corp Metabolites of 5-Fluoro-8-{4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl} quinoline and methods of preparation and uses thereof
CL2008000119A1 (es) 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
US8936787B2 (en) * 2008-04-15 2015-01-20 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Peptides promoting lipid efflux

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645681B2 (en) 1991-05-02 1994-01-20 John Wyeth & Brother Limited Piperazine derivatives
GB9514901D0 (en) 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives

Also Published As

Publication number Publication date
EA005925B1 (ru) 2005-08-25
NZ526150A (en) 2004-11-26
EP1339406A2 (en) 2003-09-03
US20030216408A1 (en) 2003-11-20
WO2002044142A3 (en) 2002-08-08
AU3765402A (en) 2002-06-11
NO20032390D0 (no) 2003-05-27
ATE269078T1 (de) 2004-07-15
IL156098A0 (en) 2003-12-23
BR0115609A (pt) 2003-11-11
HK1057864A1 (en) 2004-04-23
CN100352437C (zh) 2007-12-05
NO325501B1 (no) 2008-05-26
NO20032390L (no) 2003-07-22
WO2002044142A2 (en) 2002-06-06
US6469007B2 (en) 2002-10-22
TWI224102B (en) 2004-11-21
KR20030051879A (ko) 2003-06-25
CN1477961A (zh) 2004-02-25
US6586436B2 (en) 2003-07-01
CA2428039C (en) 2011-08-09
MXPA03004677A (es) 2003-09-05
PL363219A1 (en) 2004-11-15
EA200300619A1 (ru) 2003-10-30
KR100835552B1 (ko) 2008-06-09
AR035603A1 (es) 2004-06-16
CA2428039A1 (en) 2002-06-06
JP2004520289A (ja) 2004-07-08
US7026320B2 (en) 2006-04-11
HUP0400551A2 (en) 2006-02-28
JP4198989B2 (ja) 2008-12-17
PT1339406E (pt) 2004-10-29
DE60103927T2 (de) 2005-06-23
DE60103927D1 (de) 2004-07-22
EP1339406B1 (en) 2004-06-16
US20030022901A1 (en) 2003-01-30
TR200401546T4 (tr) 2004-09-21
AU2002237654B2 (en) 2005-07-28
ES2222401T3 (es) 2005-02-01
US20020107254A1 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
DK1339406T3 (da) Piperazinderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af lidelser i centralnervesystemet
DK1345910T3 (da) Quinazolinderivater, lægemidler indeholdende forbindelserne, deres anvendelse og fremgangsmåde til fremstilling deraf
IS6560A (is) Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni
DK1459750T3 (da) (S,S)-rebexetin til behandling af fibromyalgi og andre somatoforme lidelser
DK1156813T3 (da) Reovirus til behandling af cellulære proliferative lidelser
EE200100441A (et) Monoamiinide taasomastamise inhibiitorid kesknärvisüsteemi haiguste raviks
DK1343773T3 (da) Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
DK1474416T3 (da) Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser
EE200300167A (et) Amidoalküülpiperidiini ja -piperasiini derivaadid, neid sisaldav farmatseutiline kompositsioon ningühendite kasutamine närvisüsteemi häirete raviks
NO20043085L (no) Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet
DK1282616T3 (da) Hydroxyphenylpiperidin-4-ylidenmethylbenzamidderivater til behandling af smerter
DK1578740T3 (da) 1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
DK1228028T3 (da) Hydroxyicosatetraenoatsalte, præparater og fremgangsmåder til anvendelse til behandling af öjentörhedslidelser
DK0908458T3 (da) Substituerede pyridylmethylpiperazin- og piperidinderivater, deres fremstilling samt deres anvendelse til behandling af lidelser i centralnervesystemet (CNS)
DK2189162T3 (da) Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
NO20023448L (no) Medikamentkombinasjon for behandling av depresjon og beslektede forstyrrelser omfattende mirtazapin
DK1309322T3 (da) Anvendelse af 3-benzoylphenyleddikesyrederivater til behandling af retinale lidelser
DK1257278T3 (da) Anvendelse af mirtazapin til behandling af sövnforstyrrelser
NO20033120D0 (no) 2-arylimino-2,3-dihydrotiazolderivater, fremgangsmater for fremstilling derav og terapeutisk anvendelse derav
MXPA03004190A (es) Tratamiento de trastornos de ansiedad.
ATE374197T1 (de) Indolderivate zur behandlung von erkrankungen des zentralnervensystems
DK1341758T3 (da) Coniosetin og derivater af denne, fremgangsmåde til fremstilling og anvendelse af samme
DK1468686T3 (da) S-methyl-dihydro-ziprasidon til behandling af psykiatriske lidelser
NO20024331D0 (no) Behandling av lidelser relatert til det serotonerge system
NO20034741D0 (no) Anvendelse av desoksypeganin for behandling av sykdomsforeteelser i det sentrale nervesystem grunnet forgiftning med psykotropiske substanser